Duncan I Jodrell

Duncan I Jodrell

UNVERIFIED PROFILE

Are you Duncan I Jodrell?   Register this Author

Register author
Duncan I Jodrell

Duncan I Jodrell

Publications by authors named "Duncan I Jodrell"

Are you Duncan I Jodrell?   Register this Author

57Publications

1294Reads

34Profile Views

Quantifying drug-induced bone marrow toxicity using a novel haematopoiesis systems pharmacology model.

CPT Pharmacometrics Syst Pharmacol 2019 Sep 11. Epub 2019 Sep 11.

Safety and ADME Translational Sciences, Drug Safety and Metabolism, IMED Biotech Unit, AstraZeneca, Cambridge, UK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/psp4.12459DOI Listing
September 2019

Understanding Hematological Toxicities Using Mathematical Modeling.

Clin Pharmacol Ther 2018 10 1;104(4):644-654. Epub 2018 May 1.

Safety and ADME Translational Sciences, Drug Safety and Metabolism, IMED Biotech Unit, AstraZeneca, Cambridge, UK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/cpt.1080DOI Listing
October 2018

Cancer Immunotherapy Trials Underutilize Immune Response Monitoring.

Oncologist 2018 01 11;23(1):116-117. Epub 2017 Oct 11.

Department of Oncology, University of Cambridge, Addenbrooke's Hospital, Cambridge, United Kingdom

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1634/theoncologist.2017-0226DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5759814PMC
January 2018

New Model for Estimating Glomerular Filtration Rate in Patients With Cancer.

J Clin Oncol 2017 Aug 7;35(24):2798-2805. Epub 2017 Jul 7.

Tobias Janowitz, Edward H. Williams, Stephen J. Sammut, Andy G. Lynch, Duncan I. Jodrell, Simon Tavaré, and Helena Earl, Cancer Research UK Cambridge Institute, Tobias Janowitz, Peter B. Thomas, and Duncan I. Jodrell, University of Cambridge, Addenbrooke's Hospital, Cambridge; Andrea Marshall, University of Warwick, Coventry; Nicola Ainsworth, Queen Elizabeth Hospital, King's Lynn; Scott Shepherd, Royal Marsden Hospital, London; Jeff White, NHS Greater Glasgow and Clyde; and Patrick B. Mark, Institute of Cardiovascular and Medical Sciences, University of Glasgow, Glasgow, United Kingdom.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2017.72.7578DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5562175PMC
August 2017

A quantitative FastFUCCI assay defines cell cycle dynamics at a single-cell level.

J Cell Sci 2017 01 25;130(2):512-520. Epub 2016 Nov 25.

Cancer Research UK Cambridge Institute, University of Cambridge, Li Ka Shing Centre, Robinson Way, Cambridge CB2 0RE, UK.

View Article

Download full-text PDF

Source
http://jcs.biologists.org/content/130/2/512.full.pdf
Web Search
http://dx.doi.org/10.1242/jcs.195164DOI Listing
January 2017

Tumor-Induced IL-6 Reprograms Host Metabolism to Suppress Anti-tumor Immunity.

Cell Metab 2016 11;24(5):672-684

Cancer Research UK Cambridge Institute, University of Cambridge, Li Ka Shing Centre, Cambridge CB2 0RE, UK; Cold Spring Harbor Laboratory, Cold Spring Harbor, NY 11724, USA; Weill Cornell Medical College, New York, NY 10021, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.cmet.2016.10.010DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5106372PMC
November 2016

Understanding the Complexity of Porous Graphitic Carbon (PGC) Chromatography: Modulation of Mobile-Stationary Phase Interactions Overcomes Loss of Retention and Reduces Variability.

Anal Chem 2016 06 8;88(12):6190-4. Epub 2016 Jun 8.

Cancer Research UK Cambridge Institute, University of Cambridge, Li Ka Shing Centre , Box 278, Robinson Way, Cambridge, CB2 0RE, United Kingdom.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1021/acs.analchem.6b01167DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5362737PMC
June 2016

GEMMs as preclinical models for testing pancreatic cancer therapies.

Dis Model Mech 2015 Oct;8(10):1185-200

Cancer Research UK Beatson Institute, Glasgow, G61 1BD, UK

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1242/dmm.021055DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4610236PMC
October 2015

CHK1 Inhibition Synergizes with Gemcitabine Initially by Destabilizing the DNA Replication Apparatus.

Cancer Res 2015 Sep 3;75(17):3583-95. Epub 2015 Jul 3.

Cancer Research UK Cambridge Institute, University of Cambridge, Cambridge, United Kingdom.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/0008-5472.CAN-14-3347DOI Listing
September 2015

The use of error-category mapping in pharmacokinetic model analysis of dynamic contrast-enhanced MRI data.

Magn Reson Imaging 2015 Feb 7;33(2):246-51. Epub 2014 Nov 7.

Department of Radiology, Box 218, University of Cambridge, Cambridge Biomedical Campus, Cambridge, UK; Department of Radiology, Box 219, Cambridge University Hospitals, Cambridge Biomedical Campus, Cambridge, CB2 0QQ, UK. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.mri.2014.10.010DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4728188PMC
February 2015

The EGFR demonstrates linear signal transmission.

Integr Biol (Camb) 2014 Aug;6(8):736-42

Department of Mathematics, Imperial College London, UK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1039/c4ib00062eDOI Listing
August 2014

Design, synthesis, and biological evaluation of an allosteric inhibitor of HSET that targets cancer cells with supernumerary centrosomes.

Chem Biol 2013 Nov 24;20(11):1399-410. Epub 2013 Oct 24.

Department of Chemistry, University of Cambridge, Lensfield Road, Cambridge CB2 1EW, UK; Cancer Research UK Cambridge Institute, University of Cambridge, Li Ka Shing Centre, Robinson Way, Cambridge CB2 ORE, UK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.chembiol.2013.09.012DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3898838PMC
November 2013

Adaptive designs for dual-agent phase I dose-escalation studies.

Nat Rev Clin Oncol 2013 May 19;10(5):277-88. Epub 2013 Mar 19.

Department of Oncology, University of Cambridge, Addenbrooke's Hospital, Cambridge, UK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/nrclinonc.2013.35DOI Listing
May 2013

Anti-tumour effects of a specific anti-ADAM17 antibody in an ovarian cancer model in vivo.

PLoS One 2012 11;7(7):e40597. Epub 2012 Jul 11.

Pharmacology & Drug Development Group, Cancer Research UK Cambridge Research Institute, and Department of Oncology, University of Cambridge, Cambridge, United Kingdom.

View Article

Download full-text PDF

Source
http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0040597PLOS
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3394719PMC
January 2013

Predictive in vivo animal models and translation to clinical trials.

Drug Discov Today 2012 Mar;17(5-6):253-60

Cancer Research UK, Cambridge Research Institute, UK.

View Article

Download full-text PDF

Source
March 2012

Gene expression predicts differential capecitabine metabolism, impacting on both pharmacokinetics and antitumour activity.

Eur J Cancer 2008 Jan;44(2):310-7

Cancer Research UK Pharmacology and Drug Development Group, Edinburgh Cancer Research Centre, University of Edinburgh, Edinburgh, UK.

View Article

Download full-text PDF

Source
http://linkinghub.elsevier.com/retrieve/pii/S095980490700854
Publisher Site
http://dx.doi.org/10.1016/j.ejca.2007.10.023DOI Listing
January 2008

Aspirin activates the NF-kappaB signalling pathway and induces apoptosis in intestinal neoplasia in two in vivo models of human colorectal cancer.

Carcinogenesis 2007 May 28;28(5):968-76. Epub 2006 Nov 28.

Division of Oncology, School of Clinical and Molecular Medicine, University of Edinburgh, Colon Cancer Genetics Group, MRC Human Genetics Unit, Western General Hospital, Crewe Road, Edinburgh EH4 2XU, UK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/carcin/bgl220DOI Listing
May 2007

Structure-activity relationships for cytotoxic ruthenium(II) arene complexes containing N,N-, N,O-, and O,O-chelating ligands.

J Med Chem 2006 Nov;49(23):6858-68

School of Chemistry, University of Edinburgh, West Mains Road, Edinburgh EH9 3JJ, UK, and University of Edinburgh Centre for Cancer Research, Western General Hospital, Crewe Road South, Edinburgh EH4 2XR, UK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1021/jm060596mDOI Listing
November 2006

Validation of real-time reverse-transcription-polymerase chain reaction for quantification of capecitabine-metabolizing enzymes.

Anal Biochem 2006 Mar 21;350(1):71-80. Epub 2005 Dec 21.

Pharmacology and Drug Development Team, Cancer Research UK Centre, University of Edinburgh.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ab.2005.11.040DOI Listing
March 2006

Tuning the reactivity of osmium(II) and ruthenium(II) arene complexes under physiological conditions.

J Am Chem Soc 2006 Feb;128(5):1739-48

Contribution from the School of Chemistry, University of Edinburgh, West Mains Road, Edinburgh EH9 3JJ, U.K.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1021/ja055886rDOI Listing
February 2006

Simultaneous determination of capecitabine and its metabolites by HPLC and mass spectrometry for preclinical and clinical studies.

J Chromatogr B Analyt Technol Biomed Life Sci 2005 Nov 28;826(1-2):232-7. Epub 2005 Sep 28.

Pharmacology and Drug Development Team, Cancer Research UK Centre, University of Edinburgh, Crewe Road, Edinburgh EH4 2XR, UK.

View Article

Download full-text PDF

Source
http://linkinghub.elsevier.com/retrieve/pii/S157002320500632
Publisher Site
http://dx.doi.org/10.1016/j.jchromb.2005.09.010DOI Listing
November 2005

ERbeta isoform expression in colorectal carcinoma: an in vivo and in vitro study of clinicopathological and molecular correlates.

J Pathol 2005 Sep;207(1):53-60

Cancer Research UK Cancer and Immunogenetics Laboratory, Weatherall Institute of Molecular Medicine, John Radcliffe Hospital, Oxford, UK.

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1002/path.1807
Publisher Site
http://dx.doi.org/10.1002/path.1807DOI Listing
September 2005

Glucuronidation as a mechanism of intrinsic drug resistance in colon cancer cells: contribution of drug transport proteins.

Biochem Pharmacol 2004 Jan;67(1):31-9

Cancer Research UK, Edinburgh Oncology Unit, Western General Hospital, EH4 2XR, Edinburgh, UK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bcp.2003.07.019DOI Listing
January 2004

Glucuronidation as a mechanism of intrinsic drug resistance in human colon cancer: reversal of resistance by food additives.

Cancer Res 2003 Dec;63(23):8443-50

Cancer Research UK, Edinburgh Oncology Unit, Western General Hospital, Edinburgh, United Kingdom.

View Article

Download full-text PDF

Source
December 2003

Antisense Bcl-xl down-regulation switches the response to topoisomerase I inhibition from senescence to apoptosis in colorectal cancer cells, enhancing global cytotoxicity.

Clin Cancer Res 2003 Jul;9(7):2856-65

Cancer Research United Kingdom, Western General Hospital, Edinburgh, EH4 2XU, United Kingdom.

View Article

Download full-text PDF

Source
July 2003

Factors influencing the cellular accumulation of SN-38 and camptothecin.

Cancer Chemother Pharmacol 2002 Mar 22;49(3):194-200. Epub 2002 Jan 22.

Imperial Cancer Research Fund, Medical Oncology Unit, Western General Hospital, Edinburgh, EH4 2XU, UK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00280-001-0393-3DOI Listing
March 2002

Enhanced clearance of topoisomerase I inhibitors from human colon cancer cells by glucuronidation.

Biochem Pharmacol 2002 Feb;63(4):607-13

Imperial Cancer Research Fund, Medical Oncology Unit, Western General Hospital, EH4 2XU, Edinburgh, UK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/s0006-2952(01)00812-7DOI Listing
February 2002